Iniciamos la Reunión Temática de @NefroGalicia 2026:
➡️ Actualización en Onconefrología
📌 Dra. Pilar Oliveros, Santiago: Inmunoterapia y disfunción renal
📌 Dr. Juan Santos, Pontevedra: Deterioro de la función renal en el paciente oncológico
Identificaron anticuerpos anti-nefrina por inmunoprecipitación en personas con podocitopatias, se asociaron con proteinuria, el síndrome nefrótico y su actividad clínica
Estarían (+) en 80% de aquellos con enfermedad de cambios mínimos o FyS 1ria
NEJM 2024
10.1056/NEJMoa2314471
The third presentation in #ERA24 LBCTI is
🥁Randomized Phase 2 Trial of Felzartamab in Humoral Transplant Rejection
✍️By Katharina A. Mayer
📍Late antibody-mediated kidney transplant rejection
(AMR) is the leading cause of transplant loss
📍Long-term outcomes after AMR diagnosis remain poor
📍No therapeutic strategies have demonstrated efficacy
🚨#FLOW: The most anticipated trial of the year now published in @NEJM with #ERA24
Semaglutide 1.0mg once weekly disease modifying with kidney, CV, & mortality benefits in people w T2D+CKD, cementing itself as a new pillar of care.
🧵 on key thoughts 👇🏾
https://t.co/5fbSxPSAMM
The FLOW trial results are live at @nejm as well
#ERA24
https://t.co/C6DGQf6wVK
Primary composite kidney ✅
CV Death✅
All cause death ✅
GFR slope ✅
First MACE ✅
Kidney specific composite ✅